A Phase 2 interventional study of TU-100 and Placebo in Enhanced Recovery After Surgery, sponsored by Tsumura USA. Completed at 36 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-04-16.
Sponsored by Tsumura USA · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This multicenter, randomized, double-blinded, placebo-controlled study will evaluate the effect of TU-100 on resolution of postoperative ileus (POI) in subjects undergoing open or laparoscopic bowel resection (BR).
Subjects will be screened up to 28 days before their planned surgery and will be randomized 1:1:1 (TU-100 15 g/day: TU-100 7.5 g/day: placebo) on postoperative Day 1 before the first dose of study medication. After randomization, subjects will receive a total daily dose of TU-100 15g, TU-100 7.5 g, or matching placebo (3 times per day (TID)) until hospital discharge or ≤ 10 days (whichever is earlier). All subjects will be treated with study medication as adjunct to an enhanced recovery (ERAS) pathway for gastrointestinal (GI) recovery.
Tsumura USA is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ASA physical status
The anaesthetists’ scale of health before surgery: I is healthy, II has a mild illness that is under control, III a severe one, IV a severe illness that is a constant threat to life. V and VI are used for the critically ill and for organ donors.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects will receive a total daily dose of TU-100 5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
Drug: TU-100
Subjects will receive a total daily dose of TU-100 2.5 g TID until hospital discharge or ≤ 10 days (whichever is earlier).
Drug: TU-100
Subjects will receive placebo TID until hospital discharge or ≤ 10 days (whichever is earlier).
Drug: Placebo
Treatment with investigational product
Also known as: Daikenchuto
Treatment with placebo product
Time to Gastrointestinal Recovery (GIR)
Time to achieve recovery of GI motility as measured by a composite endpoint representing upper AND lower GI recovery
Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Time to GIR Responses
Time to achieve first toleration of solid diet AND first bowel movement (Time to GI-2), time to first toleration of clear liquids, and time to absence of distension and presence of bowel sounds and flatus
Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Time to Discharge
Time at which the subject is considered ready for discharge by the investigator based solely on GI recovery (Time to ready for discharge), and time at which the investigator writes discharge order for the subject (Time to discharge order written)
Time frame: From surgery to hospital discharge
GIR Outcome Related to Length of Hospitalization (Mean)
Mean number of days that the subject stayed in the hospital calculated based on calendar day of discharge order written
Time frame: From surgery to hospital discharge
GIR Outcome Related to Length of Hospitalization (Median)
Median number of days that the subject stayed in the hospital calculated based on calendar day of discharge order written
Time frame: From surgery to hospital discharge
Percentage of GIR Responders
Percentage of subjects who achieve GIR (GIR responders) by day
Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
POI-related Morbidity
Primary POI that is not secondary to surgical complication, such as anastomotic leak, abscess formation, or sepsis that requires readmission within 7 days of discharge, or need for postoperative nasal gastric tube insertion to manage symptoms of POI (vomiting/retching, abdominal distension)
Time frame: From the day after surgery to discharge follow-up visit (30 days (+ 15 days) after hospital discharge)
Number of Participants With Adverse Events
Number of patients with adverse events (AEs) observed following administration of TU-100.
Time frame: From baseline to discharge follow-up visit (30 days (+ 15 days) after hospital discharge)
Subject-Reported Occurrence of Nausea
Subjects will record the occurrence of nausea in their eDiaries on all postoperative in-hospital days.
Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Subject-Reported Bothersomeness of Nausea
Subjects who answered that they felt nauseous will record bothersomeness of nausea in their eDiaries on all postoperative in-hospital days. Bothersomeness is measured on a scale of 0-10 with 10 being the most bothersome.
Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Subject-Reported Occurrence of Abdominal Bloating
Subjects will record the occurrence of abdominal bloating in their eDiaries on all postoperative in-hospital days.
Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
Subject-Reported Bothersomeness of Abdominal Bloating
Subjects who answered that they felt bloated will record bothersomeness of abdominal bloating in their eDiaries on all postoperative in-hospital days. Bothersomeness is measured on a scale of 0-10 with 10 being the most bothersome.
Time frame: From the day after surgery (Day 1) until hospital discharge or Day 10 (whichever is earlier)
The study was carried out at 36 sites in the United States (US).
| Milestone | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Started | 134 | 134 | 134 |
| Safety (baseline) analysis set | 132 | 130 | 130 |
| Completed | 120 | 114 | 120 |
| Not completed | 14 | 20 | 14 |
| Withdrew: Adverse event | 1 | 0 | 1 |
| Withdrew: Lost to follow-up | 3 | 3 | 2 |
| Withdrew: Physician decision | 0 | 1 | 0 |
| Withdrew: Protocol violation | 1 | 1 | 1 |
| Withdrew: Withdrawal by subject | 5 | 6 | 4 |
| Withdrew: Subject refusal of study procedures or unable to take the study drug | 2 | 5 | 2 |
| Withdrew: Did not receive the study drug | 2 | 4 | 4 |
Time to achieve recovery of GI motility as measured by a composite endpoint representing upper AND lower GI recovery
| hours | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Time to Gastrointestinal Recovery (GIR) | 32.6 (29.7 to 41.2) | 30.8 (28.1 to 35.3) | 33.4 (29.1 to 40.9) |
Time to achieve first toleration of solid diet AND first bowel movement (Time to GI-2), time to first toleration of clear liquids, and time to absence of distension and presence of bowel sounds and flatus
| hours | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Median Time to GI-2 | 49.4 (44.8 to 57.6) | 45.2 (43.5 to 46.8) | 47.2 (41.9 to 50.2) |
| Median Time to first toleration of clear liquids | 24.0 (22.6 to 25.5) | 22.5 (21.2 to 23.6) | 23.3 (22.6 to 24.9) |
| Median Time to absence of distension and presence of bowel sounds and flatus | 38.2 (31.3 to 41.8) | 40.1 (30.7 to 43.7) | 41.2 (37.8 to 44.6) |
Time at which the subject is considered ready for discharge by the investigator based solely on GI recovery (Time to ready for discharge), and time at which the investigator writes discharge order for the subject (Time to discharge order written)
| hours | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Time to ready for discharge | 56.1 (49.4 to 66.3) | 52.2 (48.4 to 59.8) | 66.1 (52.4 to 68.2) |
| Time to discharge order written | 64.3 (50.5 to 67.8) | 58.1 (51.1 to 65.7) | 66.6 (63.5 to 69.1) |
Mean number of days that the subject stayed in the hospital calculated based on calendar day of discharge order written
| days | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| GIR Outcome Related to Length of Hospitalization (Mean) | 3.3 ± 3.07 | 2.7 ± 1.30 | 3.3 ± 3.00 |
Median number of days that the subject stayed in the hospital calculated based on calendar day of discharge order written
| days | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| GIR Outcome Related to Length of Hospitalization (Median) | 3 (1 to 28) | 2 (1 to 7) | 3 (1 to 29) |
Percentage of subjects who achieve GIR (GIR responders) by day
| percentage of subjects | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Day 1 | 20.5 | 22.7 | 24.6 |
| Day 2 | 47.0 | 55.5 | 42.3 |
| Day 3 | 18.2 | 14.1 | 20.8 |
| Day 4 | 3.8 | 1.6 | 6.2 |
Primary POI that is not secondary to surgical complication, such as anastomotic leak, abscess formation, or sepsis that requires readmission within 7 days of discharge, or need for postoperative nasal gastric tube insertion to manage symptoms of POI (vomiting/retching, abdominal distension)
| Participants | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| POI-related Morbidity | 7 | 5 | 5 |
Number of patients with adverse events (AEs) observed following administration of TU-100.
| Participants | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Number of Participants With Adverse Events | 78 | 73 | 81 |
Subjects will record the occurrence of nausea in their eDiaries on all postoperative in-hospital days.
| Participants | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Day 1 | 39 | 37 | 35 |
| Day 2 | 26 | 16 | 25 |
| Day 3 | 10 | 9 | 11 |
| Day 4 | 3 | 6 | 6 |
Subjects who answered that they felt nauseous will record bothersomeness of nausea in their eDiaries on all postoperative in-hospital days. Bothersomeness is measured on a scale of 0-10 with 10 being the most bothersome.
| score of nausea bothersomeness | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Day 1 | 5.5 ± 0.46 | 6.0 ± 0.47 | 6.1 ± 0.48 |
| Day 2 | 6.0 ± 0.53 | 4.7 ± 0.66 | 5.8 ± 0.54 |
| Day 3 | 6.7 ± 0.78 | 5.5 ± 0.86 | 6.5 ± 0.79 |
Subjects will record the occurrence of abdominal bloating in their eDiaries on all postoperative in-hospital days.
| Participants | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Day 1 | 61 | 67 | 66 |
| Day 2 | 30 | 30 | 49 |
| Day 3 | 14 | 13 | 21 |
| Day 4 | 6 | 7 | 11 |
Subjects who answered that they felt bloated will record bothersomeness of abdominal bloating in their eDiaries on all postoperative in-hospital days. Bothersomeness is measured on a scale of 0-10 with 10 being the most bothersome.
| score of bloating bothersomeness | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Day 1 | 5.2 ± 0.34 | 4.2 ± 0.33 | 5.2 ± 0.33 |
| Day 2 | 5.6 ± 0.44 | 4.4 ± 0.43 | 4.6 ± 0.36 |
| Day 3 | 5.6 ± 0.62 | 4.3 ± 0.64 | 5.0 ± 0.51 |
Collected over From baseline to discharge follow-up visit (30 days (+ 15 days) after hospital discharge). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| TU-100 15 g/Day | 0/132 (0%) | 19/132 (14.4%) | 29/132 (22%) |
| TU-100 7.5 g/Day | 0/130 (0%) | 14/130 (10.8%) | 39/130 (30%) |
| Placebo | 0/130 (0%) | 9/130 (6.9%) | 39/130 (30%) |
| Event | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| Postoperative ileusInjury, poisoning and procedural complications | 8/132 | 3/130 | 3/130 |
| HaematocheziaGastrointestinal disorders | 1/132 | 2/130 | 1/130 |
| Small intestinal obstructionGastrointestinal disorders | 0/132 | 2/130 | 1/130 |
| Clostridium difficile colitisInfections and infestations | 2/132 | 1/130 | 0/130 |
| Anastomotic leakInjury, poisoning and procedural complications | 0/132 | 1/130 | 1/130 |
| SepsisInfections and infestations | 1/132 | 1/130 | 0/130 |
| Abdominal infectionInfections and infestations | 0/132 | 0/130 | 1/130 |
| Clostridium difficile infectionInfections and infestations | 0/132 | 1/130 | 0/130 |
| Pelvic abscessInfections and infestations | 0/132 | 1/130 | 1/130 |
| DiarrhoeaGastrointestinal disorders | 1/132 | 1/130 | 0/130 |
| Event | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo |
|---|---|---|---|
| NauseaGastrointestinal disorders | 16/132 | 20/130 | 25/130 |
| VomitingGastrointestinal disorders | 10/132 | 10/130 | 8/130 |
| ConstipationGastrointestinal disorders | 2/132 | 8/130 | 7/130 |
| DiarrhoeaGastrointestinal disorders | 7/132 | 5/130 | 8/130 |
| Abdominal distensionGastrointestinal disorders | 5/132 | 7/130 | 5/130 |
Baseline analysis population includes all randomized subjects who were administered at least one dose of study treatment (safety analysis set).
| Age, Continuous(years) | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo | Total |
|---|---|---|---|---|
| Mean | 57.7 ± 13.14 | 58.3 ± 13.07 | 58.5 ± 12.09 | 58.2 ± 12.75 |
| Sex: Female, Male(Participants) | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo | Total |
|---|---|---|---|---|
| Female | 68 | 69 | 72 | 209 |
| Male | 64 | 61 | 58 | 183 |
| Ethnicity (NIH/OMB)(Participants) | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo | Total |
|---|---|---|---|---|
| Hispanic or Latino | 5 | 9 | 13 | 27 |
| Not Hispanic or Latino | 125 | 121 | 116 | 362 |
| Unknown or Not Reported | 2 | 0 | 1 | 3 |
| Race (NIH/OMB)(Participants) | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 |
| Asian | 6 | 1 | 3 | 10 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 |
| Black or African American | 13 | 6 | 10 | 29 |
| White | 109 | 118 | 110 | 337 |
| More than one race | 0 | 1 | 0 | 1 |
| Unknown or Not Reported | 4 | 4 | 7 | 15 |
| BMI(kg/m2) | TU-100 15 g/Day | TU-100 7.5 g/Day | Placebo | Total |
|---|---|---|---|---|
| Mean | 28.43 ± 6.242 | 29.46 ± 5.788 | 28.97 ± 5.649 | 28.95 ± 5.900 |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jul 2021 to primary completion in Mar 2024, 31 months.
Results were first posted in Apr 2025, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tu-100
Tsumura USA